Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 954

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 954
---
 | ​ | ​                              | ​ | 0.82 | ​ | ​ | ​ | ​                                                  | ​ |    ​ | ​ | ​ | ​ | ​                            | ​ |     ​ | ​ | ​ |
| Outstanding as of September 30, 2024                 | ​ | ​ | ​                | ​ | 5,450,941 | ​ | ​ | ​ | ​                              | $ | 0.44 | ​ | ​ | ​ | ​                                                  | ​ | 6.32 | ​ | ​ | ​ | ​                            | $ | 2,644 | ​ | ​ |
| Options exercisable as of September 30, 2024         | ​ | ​ | ​                | ​ | 4,382,734 | ​ | ​ | ​ | ​                              | $ | 0.37 | ​ | ​ | ​ | ​                                                  | ​ | 5.97 | ​ | ​ | ​ | ​                            | $ | 2,413 | ​ | ​ |
| Vested and expected to vest as of September 30, 2024 | ​ | ​ | ​                | ​ | 5,450,941 | ​ | ​ | ​ | ​                              | $ | 0.44 | ​ | ​ | ​ | ​                                                  | ​ | 6.32 | ​ | ​ | ​ | ​                            | $ | 2,644 | ​ | ​ |

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock. The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2024 and 2023 was $0.62 and $0.52, respectively. As of September 30, 2024, there was $0.4 million of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.55 years. The following table illustrates the classification of stock-based compensation in the statements of operations (in thousands):

| ​                              
 ​                              | ​ 
 ​ | ​ 
 ​ | For the Nine Months EndedSeptember 30, 
 2024                                   |   |     |   | ​ | ​ | 2023 |   |     |   | ​ 
 ​ |
|:-------------------------------|:--|: